The agreement paves the way for those over age 65 to gain access to continuous glucose monitoring, following a historic policy change.
Ascensia Diabetes Care and Dexcom have reached an agreement that should soon speed delivery of Dexcom’s G5 continuous glucose monitoring (CGM) system to eligible Medicare beneficiaries.
The deal gives Dexcom a partner for creating the “bundle” of a CGM and blood glucose monitoring system, which will meet Medicare shipping requirements and give access to those who meet CMS criteria for the system.
Earlier this year, Medicare announced it would pay for the Dexcom G5 for beneficiaries with diabetes who take insulin, use a home blood glucose monitoring system (BGMS), and perform finger stick tests at least 4 times a day. This covered virtually everyone with type 1 diabetes (T1D) and many with advanced type 2 disease (T2D).
For those who rely on CGM, this was historic news. Previously, turning 65 meant paying for the device out of pocket or giving up a tool that had helped bring unprecedented levels of glycemic control. Dexcom and advocacy groups like JDRF had worked for years on the policy change, which began with a July 2016 FDA hearing to show that it was safe to use the Dexcom G5 for dosing decisions. The Dexcom model is the only one approved by FDA for therapeutic use, which cleared the way for it to be covered by Medicare.
But the good news hit a snag when Medicare suppliers refused to ship the Dexcom G5. They wanted to know how to follow rules that require diabetes supplies to be shipped in a set, or “bundle.” Because Dexcom doesn’t make the blood glucose monitoring system needed to calibrate a CGM, it had to find a partner to meet requirements.
According to a statement from Ascensia, “The complete bundle will be available to people who are covered by Medicare and quality for therapeutic CGM.” Ascensia Diabetes Care’s Contour Next One BGMS will be included in the bundle. While separate blood glucose tests are no longer needed for each dosing decision, they are still needed twice a day to calibrate the CGM.
“For those people with diabetes who are eligible to receive the G5 through Medicare, Ascensia is thrilled to become the partner of choice for calibration of the Dexcom G5 CGM system,” said Robert Schumm, vice president and managing director of Ascensia Diabetes Care. “We believe this combination will help improve diabetes management for people on Medicare who are eligible for therapeutic CGM.”
Dexcom hailed the agreement as well. “In Ascensia, we saw a business partner that matches our own commitment to best-in-class products and services for people with diabetes. With this agreement, we are pleased to begin offering a complete bundle to Medicare-eligible patients, enabling access to the Dexcom G5 CGM system as efficiently as possible.”
CMS released a final rule to help patients obtain Children’s Health Insurance Program (CHIP) coverage and issued a proposed rule to update Medicare payment policies and rates for inpatient rehabilitation facilities; debate over if gift card incentives are acceptable in health care marketing.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
A global AIDS program that was in limbo for months got temporary relief after congressional negotiators agreed to a 1-year renewal in the next government funding package; the outcome of the November presidential election could determine the state of fetal tissue research in the US; federal officials and industry executives failed to make improvements that stop hacking attacks.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Fragmented Payer System, Vulnerable Supply Chain Among Threats to Accessing Essential Medicines
March 13th 2024During a session of the 2024 V-BID Summit, panelists Stacie Dusetzina, PhD, and Inma Hernandez, PharmD, PhD, discussed how access to essential medications is curtailed not just by the longstanding complexities of insurance design but also by emerging threats such as supply chain weaknesses and cyberattacks.
Read More
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More